Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study. Darwish M, Bugarski-Kirola D, Passarell J, Owen J, et al. J Clin Psychopharmacol 2022 Oct 3. pii: 00004714-990000000-00053.

Read + Share

Amedeo Smart

Independent Medical Education

Darwish M, Bugarski-Kirola D, Passarell J, Owen J, et al. Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study. J Clin Psychopharmacol 2022 Oct 3. pii: 00004714-990000000-00053.
PMID: 36190440